FDA Broadens Pitolisant Label - Quiz - MDSpire

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

  • By

  • Kathryn Wighton

  • February 17, 2026

  • 2 min

Share

Original Source(s)

FDA Broadens Pitolisant Label

  • by Kathryn Wighton

  • February 17, 2026

Related Content

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Arteriovenous Malformations in Children: A Pediatric Neurosurgeons Perspective

This Neuroscience Grand Rounds session, led by Muhammad Osama, MD, provides a pediatric neurosurgeon’s perspective on arteriovenous malformations (AVMs) in children, rare but high-risk vascular lesions that can lead to seizures, neurological deficits, or life-threatening hemorrhage.

  • June 19, 2026

  • 1 min
The Science of Listening

Why patient voices must shape rare disease innovation